Year |
Citation |
Score |
2020 |
Jung M, Yang Y, McCloskey JE, Zaman M, Vedvyas Y, Zhang X, Stefanova D, Gray KD, Min IM, Zarnegar R, Choi YY, Cheong JH, Noh SH, Rha SY, Chung HC, ... Jin MM, et al. Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. Molecular Therapy Oncolytics. 18: 587-601. PMID 32995483 DOI: 10.1016/J.Omto.2020.08.009 |
0.368 |
|
2020 |
Vedvyas Y, McCloskey JE, Yang Y, Min IM, Fahey TJ, Zarnegar R, Hsu YS, Hsu JM, van Basien K, Gaudet I, Law P, Kim NJ, von Hofe E, Jin MM. Publisher Correction: Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Scientific Reports. 10: 12733. PMID 32719389 DOI: 10.1038/S41598-020-69586-8 |
0.306 |
|
2020 |
Deh K, Zaman M, Vedvyas Y, Liu Z, Gillen KM, O' Malley P, Bedretdinova D, Nguyen T, Lee R, Spincemaille P, Kim J, Wang Y, Jin MM. Validation of MRI quantitative susceptibility mapping of superparamagnetic iron oxide nanoparticles for hyperthermia applications in live subjects. Scientific Reports. 10: 1171. PMID 31980695 DOI: 10.1038/S41598-020-58219-9 |
0.307 |
|
2020 |
Yang H, Puc J, Yang Y, McCloskey JE, Vedvyas Y, Li H, Min IM, Jin MM, Hofe Ev. Abstract LB-381: Mitigating on-target off-tumor cytotoxicity of EpCAM CAR-T by affinity tuning Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Lb-381 |
0.399 |
|
2020 |
Yang Y, McCloskey JE, Yang H, Puc J, Gallegos AAG, Vedvyas Y, Min IM, Hofe Ev, Jin MM. Abstract 6598: Eradication of EpCAM expressing solid tumors by low-affinity CAR T cells Immunology. 80: 6598-6598. DOI: 10.1158/1538-7445.Am2020-6598 |
0.376 |
|
2020 |
Yang Y, McCloskey JE, Vedvyas Y, Min IM, Hofe Ev, Jin MM. Abstract 6597: Highly localized, inducible interleukin-12 release augments ICAM-1 CAR T cell activity against solid tumors Immunology. 80: 6597-6597. DOI: 10.1158/1538-7445.Am2020-6597 |
0.335 |
|
2019 |
Vedvyas Y, McCloskey JE, Yang Y, Min IM, Fahey TJ, Zarnegar R, Hsu YS, Hsu JM, Besien KV, Gaudet I, Law P, Kim NJ, Hofe EV, Jin MM. Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Scientific Reports. 9: 10634. PMID 31337787 DOI: 10.1038/S41598-019-46938-7 |
0.369 |
|
2019 |
Amor-Coarasa A, Kelly JM, Singh PK, Ponnala S, Nikolopoulou A, Williams C, Vedvyas Y, Jin MM, Warren JD, Babich JW. [F]Fluoroethyltriazolyl Monocyclam Derivatives as Imaging Probes for the Chemokine Receptor CXCR4. Molecules (Basel, Switzerland). 24. PMID 31022852 DOI: 10.3390/Molecules24081612 |
0.312 |
|
2019 |
Jung M, Zaman M, Vedvyas Y, Zhang X, McCloskey JE, Yang Y, Min IM, Zamegar R, Choi YY, Cheong J, Noh SH, Rha SY, Chung HC, Jin MM. Abstract 1442: Chimeric antigen receptor T cell therapy targeting ICAM-1 in gastric cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1442 |
0.312 |
|
2019 |
Vedvyas Y, McCloskey JE, Yang Y, Min IM, Fahey TJ, Hsu YS, Hsu J, Besien KV, Gaudet I, Law P, Kim J, Hofe EV, Jin MM. Abstract 2329: Clinical manufacturing of CAR T cells targeting ICAM-1 for a phase I study against advanced thyroid cancer therapy Cancer Research. 79: 2329-2329. DOI: 10.1158/1538-7445.Am2019-2329 |
0.339 |
|
2019 |
Yang Y, Vedvyas Y, McCloskey JE, Min IM, Jin MM. Abstract 2322: ICAM-1 targeting CAR T cell therapy for triple negative breast cancer Cancer Research. 79: 2322-2322. DOI: 10.1158/1538-7445.Am2019-2322 |
0.356 |
|
2018 |
Vedvyas Y, McCloskey J, Yang Y, Min IM, Jin MM. Abstract 3592: Pharmacological intervention to temporally stimulate or inhibit ICAM-1 targeting CAR-T cells Cancer Research. 78: 3592-3592. DOI: 10.1158/1538-7445.Am2018-3592 |
0.4 |
|
2017 |
Park S, Shevlin E, Vedvyas Y, Zaman M, Park S, Hsu YS, Min IM, Jin MM. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Scientific Reports. 7: 14366. PMID 29085043 DOI: 10.1038/S41598-017-14749-3 |
0.377 |
|
2017 |
Min IM, Shevlin E, Vedvyas Y, Zaman M, Wyrwas B, Scognamiglio T, Moore MD, Wang W, Park S, Park S, Panjwani S, Gray KD, Tassler AB, Zarnegar R, Fahey TJ, ... Jin MM, et al. CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29025766 DOI: 10.1158/1078-0432.Ccr-17-2008 |
0.335 |
|
2017 |
Shevlin E, Park S, Vedvyas Y, Zaman M, Park S, Min IM, Jin MM. Abstract 3750: Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity Cancer Research. 77: 3750-3750. DOI: 10.1158/1538-7445.Am2017-3750 |
0.39 |
|
2017 |
Min IM, Vedvyas Y, Shevlin E, Zaman M, Wyrwas B, Wang W, Park S, Moore M, Scognamiglio T, Zarnegar R, Fahey TJ, Jin MM. Abstract 3624: CAR T cells targeting ICAM-1 trigger strong antitumor effects against advanced human thyroid tumors Endocrinology. 77: 3624-3624. DOI: 10.1158/1538-7445.Am2017-3624 |
0.345 |
|
2017 |
Vedvyas Y, Shevlin E, Zaman M, Min IM, Jin MM. Abstract 1707: Longitudinal and quantitative imaging of the localization, expansion, and contraction of tumor targeted adoptively transferred T cells Immunology. 77: 1707-1707. DOI: 10.1158/1538-7445.Am2017-1707 |
0.314 |
|
2016 |
Vedvyas Y, Shevlin E, Zaman M, Min IM, Amor-Coarasa A, Park S, Park S, Kwon KW, Smith T, Luo Y, Kim D, Kim Y, Law B, Ting R, Babich J, ... Jin MM, et al. Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors. Jci Insight. 1: e90064. PMID 27882353 DOI: 10.1172/Jci.Insight.90064 |
0.324 |
|
2015 |
Leelawattanachai J, Kwon KW, Michael P, Ting R, Kim JY, Jin MM. Side-by-Side Comparison of Commonly Used Biomolecules That Differ in Size and Affinity on Tumor Uptake and Internalization. Plos One. 10: e0124440. PMID 25901755 DOI: 10.1371/Journal.Pone.0124440 |
0.348 |
|
2014 |
Meng HW, Pagano JM, White BS, Toyoda Y, Min IM, Craighead HG, Shalloway D, Lis JT, Xiao K, Jin MM. Discovering aptamers by cell-SELEX against human soluble growth factors ectopically expressed on yeast cell surface. Plos One. 9: e93052. PMID 24675636 DOI: 10.1371/Journal.Pone.0093052 |
0.383 |
|
2013 |
Kang S, Lu K, Leelawattanachai J, Hu X, Park S, Park T, Min IM, Jin MM. Virus-mimetic polyplex particles for systemic and inflammation-specific targeted delivery of large genetic contents. Gene Therapy. 20: 1042-52. PMID 23759703 DOI: 10.1038/Gt.2013.29 |
0.738 |
|
2013 |
Park S, Kang S, Chen X, Kim EJ, Kim J, Kim N, Kim J, Jin MM. Tumor suppression via paclitaxel-loaded drug carriers that target inflammation marker upregulated in tumor vasculature and macrophages. Biomaterials. 34: 598-605. PMID 23099063 DOI: 10.1016/J.Biomaterials.2012.10.004 |
0.737 |
|
2012 |
Kang S, Kim CU, Gu X, Owens RM, van Rijn SJ, Boonyaleepun V, Mao Y, Springer TA, Jin MM. Complex structure of engineered modular domains defining molecular interaction between ICAM-1 and integrin LFA-1. Plos One. 7: e44124. PMID 22956999 DOI: 10.1371/Journal.Pone.0044124 |
0.717 |
|
2012 |
Hu X, Saha P, Chen X, Kim D, Devarasetty M, Varadarajan R, Jin MM. Cell surface assembly of HIV gp41 six-helix bundles for facile, quantitative measurements of hetero-oligomeric interactions. Journal of the American Chemical Society. 134: 14642-5. PMID 22888993 DOI: 10.1021/Ja301099S |
0.521 |
|
2012 |
Li J, Chang S, Liu T, Wang Q, Cui D, Chen X, Jin M, Wang B, Pei M, Wisnieff C, Spincemaille P, Zhang M, Wang Y. Reducing the object orientation dependence of susceptibility effects in gradient echo MRI through quantitative susceptibility mapping. Magnetic Resonance in Medicine. 68: 1563-9. PMID 22851199 DOI: 10.1002/Mrm.24135 |
0.468 |
|
2012 |
Gu X, Vedvyas Y, Chen X, Kaushik T, Hwang CI, Hu X, Nikitin AY, Jin MM. Novel strategy for selection of monoclonal antibodies against highly conserved antigens: phage library panning against ephrin-B2 displayed on yeast. Plos One. 7: e30680. PMID 22292016 DOI: 10.1371/Journal.Pone.0030680 |
0.54 |
|
2012 |
Wong R, Chen X, Wang Y, Hu X, Jin MM. Visualizing and quantifying acute inflammation using ICAM-1 specific nanoparticles and MRI quantitative susceptibility mapping. Annals of Biomedical Engineering. 40: 1328-38. PMID 22143599 DOI: 10.1007/S10439-011-0482-3 |
0.526 |
|
2011 |
Chen X, Wong R, Khalidov I, Wang AY, Leelawattanachai J, Wang Y, Jin MM. Inflamed leukocyte-mimetic nanoparticles for molecular imaging of inflammation. Biomaterials. 32: 7651-61. PMID 21783245 DOI: 10.1016/J.Biomaterials.2011.06.030 |
0.577 |
|
2011 |
Kang S, Park T, Chen X, Dickens G, Lee B, Lu K, Rakhilin N, Daniel S, Jin MM. Tunable physiologic interactions of adhesion molecules for inflamed cell-selective drug delivery. Biomaterials. 32: 3487-98. PMID 21306773 DOI: 10.1016/J.Biomaterials.2011.01.046 |
0.754 |
|
2011 |
Wong RL, Liu B, Zhu X, You L, Kong L, Han KP, Lee HI, Chavaillaz PA, Jin M, Wang Y, Rhode PR, Wong HC. Interleukin-15:Interleukin-15 receptor α scaffold for creation of multivalent targeted immune molecules. Protein Engineering, Design & Selection : Peds. 24: 373-83. PMID 21177283 DOI: 10.1093/Protein/Gzq116 |
0.364 |
|
2011 |
Filicori F, Kang S, Buitrago D, Keutgen XM, Chen X, Hoda R, Veach A, Jin M, Fahey TJ, Zarnegar R. The I-domain, a multifaceted nanoparticle for targeting of poorly differentiated thyroid cancer Journal of the American College of Surgeons. 213: S143. DOI: 10.1016/J.Jamcollsurg.2011.06.350 |
0.735 |
|
2010 |
Park S, Kang S, Veach AJ, Vedvyas Y, Zarnegar R, Kim JY, Jin MM. Self-assembled nanoplatform for targeted delivery of chemotherapy agents via affinity-regulated molecular interactions. Biomaterials. 31: 7766-75. PMID 20667589 DOI: 10.1016/J.Biomaterials.2010.06.038 |
0.754 |
|
2010 |
Tremblay JM, Kuo CL, Abeijon C, Sepulveda J, Oyler G, Hu X, Jin MM, Shoemaker CB. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon : Official Journal of the International Society On Toxinology. 56: 990-8. PMID 20637220 DOI: 10.1016/J.Toxicon.2010.07.003 |
0.361 |
|
2010 |
Hu X, Kang S, Lefort C, Kim M, Jin MM. Combinatorial libraries against libraries for selecting neoepitope activation-specific antibodies. Proceedings of the National Academy of Sciences of the United States of America. 107: 6252-7. PMID 20308586 DOI: 10.1073/Pnas.0914358107 |
0.731 |
|
2010 |
Owens RM, Gu X, Shin M, Springer TA, Jin MM. Engineering of single Ig superfamily domain of intercellular adhesion molecule 1 (ICAM-1) for native fold and function. The Journal of Biological Chemistry. 285: 15906-15. PMID 20304924 DOI: 10.1074/Jbc.M110.104349 |
0.363 |
|
2009 |
Mao Y, Balkin DM, Zoncu R, Erdmann KS, Tomasini L, Hu F, Jin MM, Hodsdon ME, De Camilli P. A PH domain within OCRL bridges clathrin-mediated membrane trafficking to phosphoinositide metabolism. The Embo Journal. 28: 1831-42. PMID 19536138 DOI: 10.1038/Emboj.2009.155 |
0.308 |
|
2009 |
Hu X, Kang S, Chen X, Shoemaker CB, Jin MM. Yeast surface two-hybrid for quantitative in vivo detection of protein-protein interactions via the secretory pathway. The Journal of Biological Chemistry. 284: 16369-76. PMID 19369257 DOI: 10.1074/Jbc.M109.001743 |
0.751 |
|
2008 |
Zhang H, Casasnovas JM, Jin M, Liu JH, Gahmberg CG, Springer TA, Wang JH. An unusual allosteric mobility of the C-terminal helix of a high-affinity alphaL integrin I domain variant bound to ICAM-5. Molecular Cell. 31: 432-7. PMID 18691975 DOI: 10.1016/J.Molcel.2008.06.022 |
0.312 |
|
2008 |
Hu X, Kang S, Chen X, Shoemaker CB, Jin MM. Yeast surface 2-hybrid to detect protein-protein interactions via the secretory pathway as a platform for antibody discovery Nature Precedings. 3: 1-1. DOI: 10.1038/Npre.2008.2067.1 |
0.75 |
|
2006 |
Jin M, Song G, Carman CV, Kim YS, Astrof NS, Shimaoka M, Wittrup DK, Springer TA. Directed evolution to probe protein allostery and integrin I domains of 200,000-fold higher affinity. Proceedings of the National Academy of Sciences of the United States of America. 103: 5758-63. PMID 16595626 DOI: 10.1073/Pnas.0601164103 |
0.367 |
|
Show low-probability matches. |